{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-092219","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.846146+00:00","generated_at":"2026-06-11T08:37:15.725950+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eyenovia acquires exclusive U.S. rights to Formosa's APP13007 (clobetasol) for ocular surgery inflammation/pain","bullets":["PDUFA action date for APP13007 (clobetasol) set for March 4, 2024.","Upfront payment of single-digit million in cash and stock; up to $4M in development and $80M in sales milestones.","APP13007 offers 2x/day dosing vs. standard 4x/day for post-surgical ocular inflammation/pain.","Eyenovia plans to develop clobetasol-Optejet for dry eye, a $3.6B U.S. market.","Product complements existing Mydcombi sales force; addresses >7M annual ocular surgeries."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-092219","json":"https://secwatch.observer/filing/0001104659-23-092219.json","markdown":"https://secwatch.observer/filing/0001104659-23-092219.md","text":"https://secwatch.observer/filing/0001104659-23-092219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/0001104659-23-092219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/tm2323901d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:37:15.725950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"588c5b61071a912589ed7027565f9f6b96686c3d","claim":"HYPERION DEFI, INC. entered into License Agreement with Formosa Pharmaceuticals, Inc. valued at $2 million within 45 days of the effective date of the agreement (effective 2023-08-15).","evidence_excerpt":"On August 15, 2023, Eyenovia, Inc. (the “Company”), entered into a license agreement (the “License Agreement”) with Formosa Pharmaceuticals, Inc. (“Formosa”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/0001104659-23-092219-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Formosa Pharmaceuticals, Inc."},{"label":"Value","value":"$2 million within 45 days of the effective date of the agreement"},{"label":"Effective","value":"2023-08-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}